REGENXBIO Inc. - Common Stock, par value $0.0001 per share (RGNX)

Historical Holders from Q3 2015 to Q3 2025

Symbol
RGNX on Nasdaq
CUSIP
75901B107
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
51.1M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
42M
Holdings value
$345M
% of all portfolios
0.002%
Grand Portfolio weight change
+0%
Number of holders
159
Number of buys
84
Number of sells
-78
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of REGENXBIO Inc. - Common Stock, par value $0.0001 per share (RGNX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 9.9% $46.2M 5.06M Redmile Group, LLC Jun 30, 2025
JPMORGAN CHASE & CO 7.4% $21.9M 3.7M JPMORGAN CHASE & CO. Dec 31, 2024
BlackRock, Inc. 7.3% -33.6% $21.7M -$10.6M 3.68M -32.7% BlackRock, Inc. Mar 31, 2025
BlackRock Portfolio Management LLC 6.2% $25M 3.13M BlackRock Portfolio Management LLC Jun 30, 2025
VANGUARD GROUP INC 6.02% $17.6M 2.99M The Vanguard Group Dec 31, 2024
STATE STREET CORP 4.4% $12.9M 2.19M STATE STREET CORPORATION Dec 31, 2024

Institutional Holders of REGENXBIO Inc. - Common Stock, par value $0.0001 per share (RGNX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 1.99K $19.2K -$9.1K $9.65 1
2025 Q2 42M $345M +$5.51M $8.21 159
2025 Q1 41.7M $298M -$1.5M $7.15 163
2024 Q4 42.1M $325M -$15.5M $7.73 174
2024 Q3 43.7M $458M -$8.56M $10.49 184
2024 Q2 43.8M $512M +$8.07M $11.70 181
2024 Q1 42.3M $891M +$101M $21.07 185
2023 Q4 94.5K $1.7M +$643K $17.95 3
2023 Q3 36.8M $606M -$2.77M $16.46 153
2023 Q2 36.8M $736M -$581K $19.99 161
2023 Q1 37M $700M +$18.8M $18.91 167
2022 Q4 35.6M $808M +$10.2M $22.68 175
2022 Q3 34.8M $919M -$30.1M $26.43 166
2022 Q2 36.1M $891M +$28M $24.70 150
2022 Q1 34.9M $1.16B -$13.1M $33.19 177
2021 Q4 35.5M $1.16B +$58.3M $32.70 162
2021 Q3 33.4M $1.4B +$2.28M $41.92 174
2021 Q2 33M $1.28B +$18.9M $38.85 168
2021 Q1 32.5M $1.11B +$186M $34.11 175
2020 Q4 27.3M $1.24B -$14.3M $45.36 178
2020 Q3 28M $770M -$29.2M $27.52 158
2020 Q2 29.3M $1.08B +$20.4M $36.83 170
2020 Q1 28.9M $936M -$28.8M $32.38 154
2019 Q4 29.5M $1.21B -$13.2M $40.97 174
2019 Q3 28.6M $1.02B -$22M $35.60 158
2019 Q2 29.3M $1.5B +$6.21M $51.37 177
2019 Q1 29.6M $1.7B +$15.3M $57.31 200
2018 Q4 29.8M $1.25B +$33.8M $41.95 174
2018 Q3 28.5M $2.15B +$194M $75.50 196
2018 Q2 26M $1.87B +$332M $71.75 173
2018 Q1 22.4M $668M +$29.3M $29.85 116
2017 Q4 21.6M $718M +$5.1M $33.25 105
2017 Q3 21.4M $704M -$14.4M $32.95 86
2017 Q2 22.7M $448M +$39.1M $19.75 86
2017 Q1 20.7M $398M +$92.4M $19.30 85
2016 Q4 18.3M $339M +$28.4M $18.55 77
2016 Q3 16.9M $237M +$3.13M $14.01 71
2016 Q2 17.9M $144M +$9.87M $8.00 66
2016 Q1 16.6M $180M +$4.02M $10.80 62
2015 Q4 15M $246M -$10.2M $16.60 63
2015 Q3 14.3M $310M +$310M $22.03 47